Veritas Receives Listing On The XETRA® (Frankfurt, Germany) Trading Venue
December 8, 2016, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that as of December 7th, 2016, its common shares are accepted for continuous trading on the electronic trading platform XETRA® on the Frankfurt Exchange under the symbol 2VP. Veritas Pharma’s management expects that a listing through Xetra® will provide higher liquidity and more efficient market pricing for the company’s common shares.
Veritas CEO, Dr. Franciosi, stated “this is a very exciting development and we are proud to be accepted for trading on the Xetra® platform. Xetra® is a more senior European trading venue and I believe that this will be an important step in introducing our company to a wider range of qualified retail and institutional investors.”
Xetra® is an all-electronic trading system based in Frandkfurt, Germany. It was launched in 1997 and is operated by the Deutsche Börse. Eventhough Xetra® was originally designed for the Frankfurt Stock Exchange, it has since expanded to various European exchanges. Xetra® trading venue supports more than 90 percent of all shares trading within Germany.1 Xetra®, through its platform, offers increased visibility for order depths and offers trading of stocks, funds, bonds, warrants, and commodities. “In addition to the Frankfurt trading platform, international partner exchanges also use its trading technology, including the Bulgarian Stock Exchange, the Irish Stock Exchange and the Malta Stock Exchange and Wiener Börse AG. The world’s largest exchange network connects 4,000 traders from 16 European countries plus Hong Kong and the United Arab Emirates.”1